J&J to aug­ment sur­gi­cal of­fer­ings with $3.4B ac­qui­si­tion of ro­bot­ics firm Au­ris Health

Weeks af­ter Bloomberg re­port­ed J&J $JNJ was mulling a bid for ro­bot­ics firm Au­ris Health, the health con­glom­er­ate on Wednes­day said it would fork out $3.4 bil­lion in cash for the pri­vate­ly held de­vel­op­er of ro­bot­ic tools for lung can­cer to beef up its ar­se­nal of sur­gi­cal in­ter­ven­tion­al and di­ag­nos­tic prod­ucts.

The Band-aid mak­er gen­er­at­ed med­ical de­vice sales of near­ly $27 bil­lion last year, of which about $1.34 bil­lion came from sur­gi­cal prod­uct sales. Au­ris’ prod­uct, which is cleared by the FDA for use in bron­cho­scop­ic di­ag­nos­tic and ther­a­peu­tic pro­ce­dures, al­lows doc­tors to bet­ter ac­cess small and hard-to-reach lung nod­ules ear­ly. Au­ris has plans to de­vel­op the plat­form be­yond lung can­cer, but in its cur­rent form, it will com­ple­ment J&J’s Lung Can­cer Ini­tia­tive, em­pow­er­ing the large phar­ma­ceu­ti­cal com­pa­ny to help man­age lung can­cer — one of the most lu­cra­tive phar­ma­ceu­ti­cal fields — from di­ag­no­sis to in­ter­ven­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.